Intravenous immunoglobulin for Guillain-Barré syndrome

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Guillain-Barré syndrome (GBS) is a severe, paralyzing autoimmune disorder affecting peripheral nerves.
• Intravenous immunoglobulin (IVIG) is a known treatment for various autoimmune conditions.

Purpose of the Study:

• To evaluate the efficacy of IVIG in treating Guillain-Barré syndrome.
• To compare IVIG with plasma exchange (PE) and supportive care.

Main Methods:

• Systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
• Searched Cochrane Neuromuscular Disease Group Trials Register, MEDLINE, and EMBASE.
• Included studies comparing IVIG with PE, or IVIG with supportive care.

Main Results:

• In adults with severe GBS, IVIG showed no statistically significant difference in recovery compared to PE.
• IVIG treatment was completed more often than PE.
• In children, IVIG significantly hastened recovery compared to supportive care.

Conclusions:

• IVIG is an effective treatment for GBS in children, likely hastening recovery.
• In adults, IVIG offers comparable recovery rates to PE when initiated within two weeks of symptom onset.
• Further research is needed for mild GBS, delayed treatment, and optimal dosing.